Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial by Jesús Villar et al.
Villar et al. Trials  (2016) 17:342 
DOI 10.1186/s13063-016-1456-4STUDY PROTOCOL Open AccessEvaluating the efficacy of dexamethasone
in the treatment of patients with persistent
acute respiratory distress syndrome: study
protocol for a randomized controlled trial
Jesús Villar1,2,3*, Javier Belda4, José Manuel Añón5, Jesús Blanco1,6, Lina Pérez-Méndez1,7, Carlos Ferrando4,
Domingo Martínez8, Juan Alfonso Soler9, Alfonso Ambrós10, Tomás Muñoz11, Rosana Rivas12, Ruth Corpas13,
Francisco J. Díaz-Dominguez14, Marina Soro4, Miguel Angel García-Bello15, Rosa Lidia Fernández1,2,
Robert M. Kacmarek16,17 and the DEXA-ARDS NetworkAbstract
Background: Although much has evolved in our understanding of the pathogenesis and factors affecting outcome
of patients with acute respiratory distress syndrome (ARDS), still there is no specific pharmacologic treatment for ARDS.
Several clinical trials have evaluated the utility of corticoids but none of them has demonstrated a definitive benefit due
to small sample sizes, selection bias, patient heterogeneity, and time of initiation of treatment or duration of therapy.
We postulated that adjunctive treatment of persistent ARDS with intravenous dexamethasone might change the
pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration
of mechanical ventilation and a decrease in mortality.
Methods/design: This is a prospective, multicenter, randomized, controlled trial in 314 patients with persistent
moderate/severe ARDS. Persistent ARDS is defined as maintaining a PaO2/FiO2 ≤ 200 mmHg on PEEP ≥ 10 cmH2O
and FiO2 ≥ 0.5 after 24 hours of routine intensive care. Eligible patients will be randomly allocated to two arms:
(i) conventional treatment without dexamethasone, (ii) conventional treatment plus dexamethasone. Patients in
the dexamethasone group will be treated with a daily dose of 20 mg iv from day 1 to day 5, and 10 mg iv from
day 6 to day 10. Primary outcome is the number of ventilator-free days, defined as days alive and free from mechanical
ventilation at day 28 after intubation. Secondary outcome is all-cause mortality at day 60 after enrollment.
Discussion: This study will be the largest randomized controlled clinical trial to assess the role of dexamethasone in
patients with persistent ARDS.
Trial registration: Registered on 21 November 2012 as DEXA-ARDS at ClinicalTrials.gov website (NCT01731795).
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The acute respiratory distress syndrome (ARDS) is an
inflammatory disease process of the lungs as a response
to both direct and indirect insults, characterized clinic-
ally by severe hypoxemia, reduced lung compliance, and
bilateral radiographic infiltrates [1]. The mechanisms by
which a wide variety of insults can lead to this syndrome
are not clear. Although much has evolved in our under-
standing of its pathogenesis and factors affecting patient
outcome, still there is no specific pharmacologic treat-
ment for ARDS. Despite advances in supportive mea-
sures, ARDS has a mortality rate of about 40–50 % in
most series [2]. Patients with ARDS invariably require
mechanical ventilation (MV) to decrease the work of
breathing and to improve oxygen transport. To date the
only proven, widely accepted method of MV for ARDS
is “lung-protective ventilation” using a low tidal volume
(VT) strategy plus moderate to high levels of positive
end-expiratory pressure (PEEP).
Corticoids seemed to be an ideal therapy for the acute
lung injury in ARDS, given their potent anti-inflammatory
and antifibrotic properties [3]. They switch off genes that
encode pro-inflammatory cytokines and switch on genes
that encode anti-inflammatory cytokines. It has been
reported that low doses of corticosteroids prevent an
extended cytokine response and might accelerate the
resolution of pulmonary and systemic inflammation in
pneumonia [4]. Several clinical trials have evaluated the
utility of methylprednisolone in ARDS [5–15]. None of
them has demonstrated a definitive benefit due to small
sample sizes, selection bias, patient heterogeneity, and
time of initiation of treatment or duration of therapy.
The ARDS Network performed the largest random-
ized trial of methylprednisolone versus placebo in 180
patients with ARDS of at least 7 days duration [13].
Although there was no survival benefit in the steroid
group, methylprednisolone increased the number of
ventilator-free days (VFDs) and intensive care unit (ICU)-
free days during the first month. Also, a meta-analysis of
selected trials showed that prolonged administration
of systemic steroids is associated with favorable out-
comes and survival benefit when given before day 14
of ARDS [16].
Despite these disappointing trial results, great interest
remains in the use of corticosteroids for the salvage of
ARDS patients in the early phase of their disease process,
a situation that has not been evaluated in most published
trials. Paradoxically, these hormones are given as adjunct-
ive therapy in patients with septic shock [17]. We postu-
lated that adjunctive treatment of persistent ARDS with
dexamethasone might change the pulmonary and systemic
inflammatory response and thereby reduce morbidity,
leading to a decrease in duration of MV and to a decrease
in mortality.Methods/design
Justification of the study
Currently, there is no proven pharmacologic treatment for
patients with ARDS. Protective MV is the most important
aspect of supportive care of ARDS patients. Dexametha-
sone has never been evaluated in ARDS in a randomized
controlled fashion. However, dexamethasone has potent
anti-inflammatory effects and weak mineralocorticoid ef-
fects compared with other corticosteroids [18]. It is 20 to
30 times more potent than the naturally occurring hor-
mone cortisol and four to five times more potent than
prednisone [3]. Dexamethasone has a long-lasting effect,
allowing for a once-a-day regimen [18]. Whether addition
of dexamethasone to conventional supportive treatment
benefits ARDS patients is unknown, it has been used in
patients with pneumonia [18], septic shock [19], meningi-
tis [20], and other causes of ARDS [21].
We justify the need of our study based on the positive
results of two recent clinical trials: (i) Meijvis et al. [18]
showed that dexamethasone (5 mg/day) for 4 days was able
to reduce length of hospital stay in 304 patients with bac-
terial pneumonia when added to conventional treatment;
(ii) Azoulay et al. [21] showed that dexamethasone (10 mg/
6 h), when added to chemotherapy and conventional ICU
management, caused less respiratory deterioration and
lower ICU mortality in 40 patients with acute lung injury
resulting from leukemia. Our goal is to examine the effects
of dexamethasone on length of MV (assessed by number
of ventilator-free days) and on 60-day mortality, in patients
admitted into a network of Spanish intensive care units
(ICUs) who still meet ARDS criteria at 24 hours after
ARDS onset despite routine intensive care management.
Study design
The DEXA-ARDS study is a prospective, multicenter,
randomized, controlled trial in 314 patients with persist-
ent ARDS admitted into a network of 18 ICUs from uni-
versity and community hospitals in Spain (Appendix 1).
The trial has been designed in accordance with the
fundamental principles established in the Declaration of
Helsinki, the Convention of the European Council re-
lated to human rights and biomedicine, and the Univer-
sal Declaration of UNESCO on the human genome and
human rights, and within the requirements established
by Spanish legislation in the field of biomedical research,
the protection of personal data, and bioethics, which
was classified by the Spanish Agency of Drugs and
Medical Devices (Agencia Española del Medicamento y
Productos Sanitarios) as a clinical randomized study
with drugs on 21 November 2012 and registered on 21
November 2012 at http:/www.clinicaltrials.gov with identi-
fication no. NCT01731795. The study was approved by
the referral Ethics Committee (Hospital Clínico Universi-
tario de Valencia, Valencia, Spain) and the institutional
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file 1). For inclusion into the study, signed written in-
formed consent from the patient or the patient’s personal
legal representative will be provided (Additional file 2).
See Additional file 3 for the SPIRIT checklist of the study
protocol.Study population
To be eligible for inclusion into this study (day 0), each
patient (male or female) must fulfill the following inclu-
sion criteria during screening and prior to enrollment into
the study: age ≥18 years, be intubated and mechanically
ventilated, and have acute onset of ARDS, as defined by
the American-European Consensus Conference (AECC)
criteria for ARDS [22] or as moderate/severe ARDS by the
Berlin criteria [23], which include: (i) having an initiating
clinical condition (pneumonia, aspiration, inhalation in-
jury, sepsis, trauma, acute pancreatitis, etc.); bilateral infil-
trates on frontal chest radiograph, (ii) absence of left atrial
hypertension, a pulmonary capillary wedge pressure less
than 18 mmHg, or no clinical signs of left heart failure,
(iii) hypoxemia (as defined by a ratio between partial pres-
sure of oxygen in arterial blood and fraction of inspired
oxygen (PaO2/FIO2) ≤ 200 mmHg on PEEP ≥ 5 cmH2O,
regardless of FiO2). Patients will be excluded from study
participation if any of the following are present: pregnancy
or active lactation, enrollment in another experimental
treatment protocol, brain death, terminal-stage cancer or
other terminal disease, having do-not-resuscitate orders,
immunocompromised, receiving corticosteroids or im-
munosuppressive drugs, more than 24 hours elapsed after
initially meeting the ARDS criteria before consent and
results of initial standard ventilator settings could be
obtained, severe chronic obstructive pulmonary disease,
or congestive heart failure.Enrollment into the study and randomization
For the present study, onset of ARDS was defined as
the day and time in which the patient first met ARDS
criteria [22, 23]. Screened patients will be considered
for enrollment immediately prior to randomization
and to the first dose of study medication on day 1 if
they still meet the ARDS inclusion criteria at 24 hours
after ARDS onset, assessed on standard ventilator set-
tings. Arterial blood gases and hemodynamic and data
will be obtained on the following mandatory standard ven-
tilator settings: volume assist/control mode, VT 7 ml/kg
predicted body weight (PBW), inspiratory:expiratory (I:E)
time ratio 1:1, ventilator rate to maintain a partial pressure
of carbon dioxide (PaCO2) of 35 to 50 mm Hg, on FiO2 ≥
0.5 and PEEP ≥ 10 cmH2O) [24]. If under these ventilator
settings, the PaO2/FiO2 is ≤ 200 mmHg, the patient will be
eligible for randomization.Eligible, informed consented patients will be ran-
domly allocated to two arms: (i) conventional treatment
without dexamethasone and (ii) conventional treatment
plus dexamethasone. Randomization will be performed
by blocks of ten opaque, sealed envelopes sent to each
participating ICU, according to a computer-generated
random-number table. Randomization will be based on
one-to-one allocation of prenumbered envelopes. As
requested, a second block of ten sealed envelopes will
be sent to those participating ICUs with high enroll-
ment rates.
Ventilatory management and dexamethasone therapy
Both treatment arms will follow current guidelines for
supportive care, including antibiotic therapy. Although
patient care is not strictly protocolized, physicians are
asked to follow current standards for critical care man-
agement. For ventilatory management, enrolled patients
in both arms will be ventilated with a VT of 4 to 8 ml/kg
PBW, a plateau pressure < 30 cmH2O, at a respiratory
rate to maintain PaCO2 35 to 50 mmHg and PEEP and
FiO2 combinations that maintain a PaO2 > 60 mmHg or
a peripheral capillary oxygen saturation (SpO2) > 90 %.
Patients in the dexamethasone group will be treated with
a daily dose of 20 mg iv from day 1 to day 5 and 10 mg
iv from day 6 to day 10. We have selected this dose and
time of treatment by doubling the dose used by Meijvis
et al [18], since our patients are sicker, and half the dose
used by Azoulay et al. [21] to avoid development of neu-
tropenia. Our therapeutic regime is dose-equivalent to
that from the Steinberg et al trial [13] with methylpred-
nisolone. Treatment with dexamethasone will be main-
tained for a maximum of 10 days or until extubation (if
occurring before day 10 after study enrollment) (Fig. 1).
For weaning from MV in both groups, patients will be
assessed daily for readiness for a spontaneous breathing
trial based on the ARDSNet protocol [25].
General procedures
All participating patients, regardless of the study arm
into which they are randomized, will be monitored and
managed following general standard of care practices aimed
at maintaining optimal conditions. Data from lung mechan-
ics, gas exchange, and hemodynamics will be collected on
days 0, 1, 3, 6, and 10, and every 7 days, including the last
day of MV (Fig. 2). On each day, the lowest and the highest
values of each of the following parameters will be recorded:
(i) MV and gas-exchange parameters, including VT (ml/kg
PBW), respiratory rate, plateau pressure, PEEP, PaO2/FiO2,
PaCO2; (ii) hemodynamics, including blood pressure, heart
rate, need for vasoactive drugs; (iii) safety, including fre-
quency of complications (barotrauma, sepsis, pneumonia,
etc.), routine biochemistry and hematological tests; (iv) crit-
ical care severity scores recorded on days 0 and 1, such as
Fig. 1 Study design diagram
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(APACHE II) score [26] and lung injury severity score
[27]; (v) total number of extrapulmonary organ failures
included in the sequential organ failure assessment
(SOFA) scale [28] will be documented daily. Any organ
failure occurring during the 6-hour period before death
will be considered part of the terminal event and not
counted [29]. We will use standard definitions for sep-
sis and organ failures [28, 30, 31]. We will also monitorFig. 2 Schedule of eventsICU and hospital mortality, and duration of MV. Pa-
tients will be followed up for 60 days after enrollment.Primary and secondary outcomes
The primary outcome of interest is the number of
ventilator-free days (VFDs) at 28 days [32], defined as
days alive and free from MV at day 28 after intubation.
For subjects ventilated ≥ 28 days and for subjects who
Villar et al. Trials  (2016) 17:342 Page 5 of 10die, VFD is 0. The secondary outcome of interest is all-
cause 60-day mortality.
Sample size calculations and interim analysis
Since there are no previous pharmacologic studies in pa-
tients with persistent ARDS, we estimated the sample size
on the assumption that dexamethasone could increase
VFDs by ≥ 2 days (from an estimated reference VFDs of
9 days), or would reduce overall 60-day mortality by ≥ 15 %
(from a reference control mortality of 50 %). Depending on
the estimated standard deviation for the mean VFDs and
the expected 60-day mortality rate, we studied various
group-size scenarios with cohorts of 147 to 157 patients in
each arm to detect these differences with a power of 80 %
and a type 1 error of 5 % (two-sided). A population size of
157 patients for each arm (a total of 314 patients) will
satisfy all scenarios. No patient loss has been considered.
We will only analyze patients that are enrolled and ran-
domized. The power analysis has been performed accord-
ing to Schoenfeld et al [32] (Fig. 3). Since we need three
probabilities for estimating VFD and sample size (Table 1,
highlighted in yellow), we selected three probabilities com-
patible with our hypothesis (using the Mann-Whitney test).
There will be one single formal interim analysis for
both efficacy and futility. This analysis will be performed
once 50 % of the planned patients have been randomized
and initiated treatment and have been followed up to
day 60. To protect against an obvious lack of efficacy,
failure to achieve an increase of VFDs ≥ 1 day will justify
stopping the trial. To protect against a clear improve-
ment of efficacy, achieving a statistically significant
difference in VFDs ≥ 3 days or an absolute difference in
60-day mortality ≥ 15 % (two-tailed significant difference
p < 0.025) will justify stopping the trial. The interim
analysis will be performed at the coordinating center
(Hospital Universitario Dr. Negrín, Las Palmas de Gran
Canaria, Spain) by an external, independent data and
safety monitoring board. Investigators enrolling patients
will be blinded to the results of this interim analysis if
the stopping rule is not applied.
Statistical analysis of data
Data will be collected in each participating ICU using a
standardized form. Data will be transmitted to the coordin-
ating center whenever a patient dies or is discharged from
the hospital. Before exporting the data into a computerized
database at the coordinating center, a trained data collector
from the coordinating center will check the completeness
and the quality of information. Logical checks will be per-
formed for missing data and to find inconsistencies, espe-
cially regarding clinical diagnosis, date, and severity scores.
If necessary, the data collector will contact the investigator
by phone to validate the data or reformat the data for entry
into the database.The primary endpoint is the number of ventilator-free
days (VFDs) to day 28 after intubation, where all deaths
will be awarded zero days. The analysis of VFDs will be
performed as intention to treat. By definition, all patients
will be mechanically ventilated at the time of ARDS onset.
Secondary endpoint is mortality at 60 days (the patient
could die before that time period, or could be alive in the
ICU, in the hospital or at home). Other outcome end-
points include pulmonary complications (barotrauma),
duration of MV, number of extrapulmonary organ failures,
and hospital mortality.
Descriptive statistics will be expressed as mean ± SD or
median and interquartile range, depending on the nature
and distribution of the variables. Inferential statistics will
use estimates of the mean of the differences and their
95 % confidence intervals. Variables normally distributed
will be compared with the Student’s t test. For variables
without a normal distribution, the Mann-Whitney U rank
test will be used for comparison. Categorical variables will
be compared using Fisher’s exact test. Probability of sur-
vival at 60 days after randomization will be analyzed ac-
cording to the Kaplan-Meier method, and the results
compared with the log-rank test. The relative risks and
their 95 % confidence intervals will be estimated. For all
these comparisons, we will consider a difference to be sta-
tistically significant if p < 0.05 (two-sided).
Trial organization
The steering committee is constituted by the study princi-
pal investigators who contributed to its design and
approved the final protocol (Appendix 2). The executive
committee comprises the main investigators of each partici-
pating center and is responsible for administrative, trial,
and data management. The data and safety monitoring
board is composed of external, independent experts in crit-
ical care medicine, mechanical ventilation and ARDS, and
with the general data provided by three internal members,
it will recommend the continuation or discontinuation of
the trial based on the data from the interim analysis
(Appendix 2). The trial management team comprises a
chief investigator, a project manager, a statistician, a clinical
epidemiologist, and an investigator expert in clinical trials.
The responsibilities of this team are:
(i) Planning and conducting the study: designing
the protocol, case report forms, designing the
investigator manual, and managing and
controlling the data quality.
(ii) Research center support: assisting the centers
with the administrative submission, monitoring
recruitment rates, providing sealed randomization
envelopes, taking actions to increase patient
enrollment, monitoring follow-up, auditing, and
sending study materials to the research centers.
Fig. 3 Estimation of samples size calculations based on expected ventilator-free days and mortality. Power analysis has been performed according
to Schoenfeld et al [32]. Since we need three probabilities (see Table 1, text highlighted in yellow), we have selected three probabilities compatible with
our hypothesis (using Mann-Whitney test). We hypothesized that patients in the experimental treatment group have a greater probability of being
weaned earlier from the ventilator (0.0641 vs. 0.481) and a lower probability of dying (0.0345 vs. 0.05) for each day of the follow-up period
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Table 1 Calculations for the sample size
VFDs Probability of getting
off ventilation alive
Probability of death Probability of receiving
ventilation
Expected mortality
Mean SD pa pd po 60-day mortality
Control group 9.0 10.7 0.0481 0.0500 0.9019 0.4814
Experimental group 12.0 10.8 0.0641 0.0345 0.9014 0.3308
Difference 3.0 0.0160 -0.0155 -0.0005 -0.1506
VFD ventilator-free days, SD standard deviation
Villar et al. Trials  (2016) 17:342 Page 7 of 10(iii) Producing a monthly study newsletter (Dexanews).
(iv) Programming a research-in-progress meeting every
6 months with principal investigators from all sites.
(v) Statistical analysis and research reporting: interim
and complete statistical analysis and helping in
writing the final manuscript.
Discussion
This is the first randomized controlled trial designed to
evaluate the efficacy of dexamethasone in patients with
persistent ARDS and managed with a protective ventila-
tory strategy, which includes the use of low VT, applica-
tion of moderate to high levels of PEEP, and limitation
of the plateau pressures below 30 cmH2O.
Corticosteroids have been the most widely used medi-
cations for ARDS since the first clinical description of
the syndrome [33]. However, after 50 years of intense re-
search, the impact of corticosteroids on ARDS prognosis
remains controversial despite numerous observational
studies and randomized controlled trials. Published studies
exhibit strong publication bias, report inconsistent results
and contain a strong heterogeneity due to the inclusion of
a wide variety of disease entities and severities and the lack
of an early standardized criteria for assessment of lung
severity at the time of patient enrollment [34]. Current
clinical practice guidelines for ARDS do not recommend
corticosteroid therapy, although corticosteroids are given
for many reasons, particularly in such potentially fatal
conditions as severe pneumonia [35]. The main adverse
effect of corticosteroid therapy seems to be hyperglycemia.
With the dose and period of treatment suggested in this
trial, it will be extremely rare that the prevalence of
dexamethasone-induced hyperglycemia would be greater
than the associated prevalence of hyperglycemia seen in
the acute phases of critical illness [36]. Although the po-
tential disadvantages of corticosteroids should be weighed
against the potential benefits, none of the trials performed
to date in critically ill patients has shown that the treat-
ment with corticosteroids is harmful [37].
There are major differences between our study and
other randomized controlled trials evaluating the impact
of corticosteroids in patients with ARDS. First, all the tri-
als published before 2005 evaluated the use of steroids in
patients treated with nonprotective MV [5, 7, 8, 10–12].Second, none of the trials has used the same timing, dos-
age and type of corticosteroids. Third, none of the trials
has specifically evaluated the use of dexamethasone in
ARDS. Fourth, none of the trials has consistently reas-
sessed patients at 24 hours after ARDS onset to ensure
that only patients with early established ARDS were ran-
domized. As a result, those previous studies enrolled
patients with less or greater lung injury but well beyond
the 48 hours of the disease process. It has been shown that
ARDS is characterized by an overwhelming pulmonary
and systemic inflammatory response within 48 hours
resulting in exacerbated pulmonary inflammation and
fibroproliferation [38]. Failure to repair tissue damage
during the first 48 hours results in an ongoing, self-
perpetuating inflammation with subsequent loss of lung
function and associated increased mortality rate. In our
trial, we will ensure that all enrolled patients have estab-
lished moderate/severe ARDS after 24 hours of meeting
the AECC/Berlin definition while on standard ventilator
settings. Therefore, the cohort of patients that we will
study is different from those studies by the ARDSNet [13]
and others [5–8, 10–15]. Finally, although a recent ana-
lysis of individual data from four randomized controlled
trials with a trial-level meta-analysis [39] showed that early
and prolonged corticoid treatment accelerated resolution
of ARDS and decreased hospital mortality, none of the in-
dividual trials reported in that and other meta-analyses is
able to confirm the favorable impact of corticosteroids
therapy on the overall mortality of ARDS [16, 34, 39].
Ideally, our study is an adequately powered randomized
trial to definitively answer this question.
It should be emphasized that since no studies have been
performed to date examining the potential beneficial ef-
fects of dexamethasone in ARDS, we only can speculate
about the potential limitations of the study. First, if our
hypothesis is supported, we cannot generalize our findings
to all patients with ARDS. Second, our study design will
not allow us to conclude whether administration of dexa-
methasone for longer or shorter period of time would
have the same effects. Third, our study design will not
allow us to conclude whether a different dosage would
have different effects. Also, since no studies have been
performed to date examining the potential beneficial ef-
fects of dexamethasone in ARDS, we only can speculate
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pothesis is correct, this study will mark an inflection point
in the treatment of patients with severe acute lung injury.
Second, if our hypothesis is correct, it will be the first time
that treatment with a well-known anti-inflammatory drug,
such as dexamethasone, will decrease morbidity and mor-
tality of patients with established ARDS. If our hypothesis
is correct, expected benefits for public health will include:
earlier “liberation” of patient from MV; less probability of
occurrence of ICU-associated “dangerous and/or lethal”
complications (shock, sepsis, pneumonia, multiple system
organ failure); earlier discharge from the ICU; earlier
discharge from the hospital, and marked reduction of
health care cost.
Trial status
The first patient was enrolled on 28 March 2013. Expected
duration of the study is 50 months.
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